Xenon Pharmaceuticals shares traded at $62.67, exceeding the average analyst 12-month target of $56.39 — a $6.28 premium (~11.1% above the target). The article notes that analysts typically must react (e.g., re-rate or adjust targets) when a stock reaches its target, but provides no specific analyst updates.
Xenon Pharmaceuticals shares traded at $62.67, exceeding the average analyst 12-month target of $56.39 — a $6.28 premium (~11.1% above the target). The article notes that analysts typically must react (e.g., re-rate or adjust targets) when a stock reaches its target, but provides no specific analyst updates.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
